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A B S T R A C T
A rapid and sensitive liquid chromatography tandem mass spectrometry method was es-
tablished and validated for determination of melatonin in dog plasma using desvenlafaxine
as an internal standard (IS). Plasma samples were pretreated by liquid–liquid extraction with
ethyl acetate. Chromatographic separation was carried out on a C18 column at a flow rate
of 0.2 ml/min by an isocratic mobile phase of methanol : 5 mM ammonium acetate : formic
acid (40:60:0.1, v/v/v). Positive ion mode detection was performed using multiple reaction
monitoring (MRM) at m/z 233.2→174.2 for melatonin and m/z 264.2→58.2 for desvenlafaxine.
The method was linear in the concentration range of 0.020–10 ng/ml with a correlation co-
efficient ≥0.996. The intra- and inter-assay precision (%RSD) values were within 12.6% (LLOQ
15.2%), and accuracy (%RE) ranged from −1.8% to 5.0% (LLOQ ±16.5%). The total analysis time
was 3.0 min. The method was fully validated and successfully applied to a pharmacoki-
netic study of melatonin prolonged-release tablet in Beagle dogs. The values of half-life and
Tmax were similar to the corresponding data reported before.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Melatonin (N-acetyl-3-(2-aminoethyl)-5-methoxyindole), an en-
dogenous hormone, is a predominant product of the pineal
gland. It is secreted in a rhythm that is strictly dependent on
the light–dark cycle. The melatonin plasma concentration rises
in the early night, peaks at about midnight and then declines
during the daytime [1]. Melatonin also has an age-related
rhythm. The reduction of melatonin contributes to the aging
process and may shorten the life span [2]. Studies have shown
that exogenous melatonin administration is useful for treat-
ing circadian disruptions, e.g., insomnia [3], jet lag [4]. Moreover,
melatonin has pharmacological effects on the treatment of Al-
zheimer’s disease [5], Parkinson disease [6], glaucoma [7],
depressive disorder [8], breast [9] and prostate cancer [10], hepa-
toma [11] and melanoma [12]. Unfortunately, a substitution
therapy is not easily achieved with melatonin because of its
relatively poor bioavailability [13] and rapid elimination [14].
In 2007, a prolonged-release formulation of melatonin
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(Circadin®, Neurim Pharmaceuticals, Tel-Aviv, Israel) was ap-
proved in Europe by the European Medicines Agency (EMEA)
for the treatment of insomnia in patients aged >55 years [15].
Prolonged-release formulation is often used in clinical treat-
ment to maintain longer effective concentrations and lower
incidences of side reactions.
Several methods for the determination of melatonin in bio-
logical fluids have been reported, such as enzyme immunoassay
(EIA) [16], radioimmunoassay (RIA) [17], high-performance liquid
chromatography with fluorescence [18–20] or electrochemi-
cal detection [21–23], capillary electrophoresis-ultraviolet
detection (CE-UV) [24], gas chromatography–mass spectro-
metry(GC-MS/MS) [25–29] and liquid chromatography coupled
with tandem mass spectrometry (LC-MS/MS) [30–41]. Perhaps
immunoassay is widely used in the determination of melato-
nin, but even so, it has the disadvantage of cross reactivity
affected by structurally similar compounds. HPLC coupled with
fluorescence or electrochemical detection, CE-UV or GC-MS was
not adequate to perform a pharmacokinetic study of melato-
nin because of its complex sample preparation procedure while
LC-MS/MS demonstrates great selectivity and relatively good
sensitivity. Wang et al. established an LC-MS/MS method to de-
termine melatonin in dog plasma with an LLOQ of 0.001 ng/ml,
whereas it suffered from tedious sample extraction, extrava-
gant plasma of 0.55 ml and long analytical time (11 min) [35].
Yang et al. developed an LC-MS/MS method using liquid–
liquid extraction with an LLOQ of 0.01 ng/ml [37]. However, a
bulk plasma volume of 0.5 ml and a large injection volume of
20 μl were used in this method and the analytical time was
about 6 min.
In this paper, we developed a rapid and sensitive LC-MS/
MS method to determine melatonin in dog plasma.The method
was greatly suitable for high throughput analysis and was suc-
cessfully applied to a pharmacokinetic study of melatonin in
Beagle dogs after an oral dose of 2.0 mg prolonged-release mela-
tonin tablet.
2. Materials and methods
2.1. Chemicals and reagents
Melatonin (99.5% purity) and desvenlafaxine succinate (used
as IS, 100.8% purity) were obtained from Wuhan Xingjialing Bio-
tech Co. Ltd (Wuhan, China) and Shenzhen Jianzhu Bio-tech
Co. Ltd (Jinan, China), respectively. Melatonin prolonged-
release tablets (2 mg/tablet, Lot: 457026302, RAD Neurim
Pharmaceuticals EEC Ltd., Israel) were a gift from Beijing
Boaiwangkang Bio-tech Co. Ltd (Beijing, China). Methanol (HPLC
grade) was purchased from Dikma Technology (Lake Forest, CA,
USA). Formic acid (HPLC grade) was purchased from ANPEL Sci-
entific Instrument Co. Ltd (Shanghai, China). Ethyl acetate,
ammonium acetate and anhydrous sodium carbonate (ana-
lytical grade) were purchased from Tianjin Damao Chemical
Technology Co. Ltd (Tianjin, China). Purified water was pur-
chased from Wahaha Co. Ltd (Hangzhou, China) and filtered
through a 0.22 μm membrane filter before use.
2.1.1. Chromatographic and mass spectrometric conditions
Chromatographic separation was accomplished on a Luna C18
column (2.0 × 50 mm, 3 μm, Phenomenex Technology, USA).
HPLC analysis was performed on an Agilent 1290 LC system
(Agilent, Santa Clara, CA, USA) equipped with a bin pump
(G4220A), an auto-sampler (G4226A) and a thermostated column
compartment (G1316C). An isocratic mobile phase of metha-
nol : 5 mM ammonium acetate: formic acid (40:60:0.1, v/v/v) was
applied at a flow rate of 0.20 ml/min. The injection volume was
10 μl. The temperatures of the column and auto-sampler were
kept at 35 °C and 4 °C, respectively.
Mass spectrometry detection was carried out on an AB Sciex
(Applied Biosystem/MDS SCIEX, Foster City, CA, USA) API4000
mass spectrometer, using TurboionsprayTM source in positive
ion mode. Quantification was performed using multiple reac-
tion monitoring (MRM) mode with the transitions of m/z
233.2→174.2 for melatonin and m/z 264.2→58.2 for desven-
lafaxine. The optimal source parameters were as follows:
collision-activated dissociation gas (CAD) 6 psi, curtain gas (CUR)
30 psi, nebulizer gas (gas 1) 50 psi, heater gas (gas 2) 50 psi, ion
spray voltage 5500 V and source temperature 500 °C. The com-
pound dependent parameters collision energy (CE) was set at
19 V for melatonin and 39 V for IS. Declustering potentials (DP)
for melatonin and IS were 60 and 52 V, respectively. Entrance
potential (EP) and cell exit potential (CXP) for both melatonin
and IS were maintained at 10 and 15 V, respectively. Quadru-
pole 1 and quadrupole 3 were kept at unit resolution and dwell
time was set at 100 ms. System control and data analysis was
performed by AB Sciex Analyst software (version 1.5.2).
2.2. Preparation of standard solution, calibration curve
and quality control samples
Stock standard solutions of melatonin and desvenlafaxine (IS)
were prepared in methanol at a concentration of 1.0 mg/ml.
A series of melatonin working standard solutions with con-
centrations in the range of 0.20–100 ng/ml were obtained by
further dilution of the stock solution with methanol. The IS
working solution was diluted with methanol to a final con-
centration of 12.5 ng/ml. All solutions were stored at −20 °C and
brought to room temperature before use.
The plasma calibration standards of melatonin with final
concentrations of 0.020, 0.050, 0.20, 1.0, 5.0, 10 ng/ml were pre-
pared as follows: a 20 μl aliquot of melatonin working standard
solutions was spiked into a 10 ml glass tube and the solvent
was evaporated to dryness under air stream. A 200 μl aliquot
of blank plasma was then added to each tube. Quality control
(QC) samples of 0.040, 0.40 and 8.0 ng/ml were prepared in the
same way as calibration standards. Additional validation QCs
were prepared at 0.020 ng/ml to test LLOQ. The spiked plasma
(calibrators and QCs) were treated according to the sample
preparation described below.
2.3. Sample preparation
To a 200 μl aliquot of each plasma sample, 20 μl of IS solution
(12.5 ng/ml desvenlafaxine in methanol) and 50 μl of 1 M sodium
carbonate were added and vortex-mixed for 10 s. After the ad-
dition of 1 ml of ethyl acetate and 100 μl of water, the sample
was shaken on a reciprocating shaker at 240 circles per minute
for 10 min, followed by centrifugation at 4250 × g for 5 min.The
organic layer was separated and evaporated to dryness at 40 °C
under an air stream. The residue was reconstituted in 100 μl
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of the solution of methanol : 5 mM ammonium acetate (40:60,
v/v) and 10 μl was injected for LC-MS/MS analysis.
2.4. Method validation
A full validation process was conducted according to the Guid-
ance for Industry Bioanalytical Method Validation, recom-
mended by FDA [42].
Selectivity of the method was evaluated by analyzing six
blank plasma samples to investigate the potential interfer-
ences at the retention times for the analyte and IS. Carry over
was carried out by injecting blank plasma samples after the
injection of the upper limit of quantification (ULOQ) sample
(10 ng/ml). Cross-talk of multiple reactions monitoring (MRM)
for the analyte and IS was checked using the highest stan-
dard on calibration curve and working solution of IS.
Linearity of the method was assessed by processing (in du-
plicate) a six-point calibration curve over the concentration
range of 0.020–10 ng/ml. Calibration curves were built by plot-
ting the peak area ratios of the analyte to IS versus the nominal
concentrations of the analyte with weighted (1/x2) least-
squares linear regression. The correlation coefficient (r) of a
calibration curve should be more than 0.99. The lowest limit
of quantification (LLOQ) was defined as the lowest concentra-
tion on the calibration curve with a signal-to-noise ratio of at
least 10.The back-calculated concentrations at each point have
to be within ±15% deviation from the nominal value except for
LLOQ where deviation should be within ±20%.
Intra-day and inter-day precision and accuracy were
determined by analyzing six replicate QCs at plasma concen-
trations of 0.020 (LLOQ), 0.040, 0.40 and 8.0 ng/ml on the same
day and on three consecutive days, respectively. The criteria
for the data included accuracy (relative error, RE) within ±15%
(±20% for LLOQ) and a precision (relative standard deviation,
RSD) not exceeding 15% (20% for LLOQ).
The extraction recovery and matrix effect of melatonin and
IS were determined by analyzing six replicates of plasma
samples at three QC levels of 0.040, 0.40 and 8.0 ng/ml of mela-
tonin and IS concentration of 1.25 ng/ml. The recovery was
calculated by comparing the peak areas obtained from ex-
tracted spiked samples with the mean peak area of samples
spiked post-extraction at corresponding concentrations. The
matrix effect was measured by comparing the peak areas of
analyte added into post-extracted blank plasma samples with
the mean peak area obtained from corresponding standard so-
lution of the analyte prepared in the reconstitution solution.
The variability (RSD) of the matrix effect at each concentra-
tion should be less than 15% [43].
The stability of melatonin in dog plasma was assessed by
analyzing triplicates of QCs at 0.040 and 8.0 ng/ml under dif-
ferent storage conditions.These QCs were analyzed after storage
at room temperature for 4.0 h (bench-top stability), at −70 °C
for 25 d (long-term stability), after three freeze–thaw cycles at
−70 °C (freeze–thaw stability), after storage with dry ice for 2.0 h
(transportation stability), and in processed samples at 4 °C for
24 h (auto-sampler stability).
The concept of incurred sample reanalysis (ISR) was first
introduced in the 2007 White Paper [44]. And then, running an
ISR was recommended in the 2011 European Medicines Agency
Guidance and the 2013 FDA Guideline Draft. Based on these
guidelines, 15% of the samples from six different dogs at Cmax,
the time of absorption and elimination phase in pharmaco-
kinetic profile were prepared. Two-thirds (67%) of the repeated
sample results should be within 20%, which is determined with
the following equation: RE% = (Repeat − Original)/Mean*100%.
2.5. Pharmacokinetic study
Six Beagle dogs (10.10 ± 1.10 kg, three male and three female)
were supplied by Shenyang Kangping Laboratory Animal In-
stitute (Shenyang, China). They were housed under standard
conditions and had ad libitum access to water. All experimen-
tal procedures were performed in accordance with the
guidelines of the Experimental Animal Care and Use Commit-
tee of Shenyang Pharmaceutical University (Shenyang, China).
Dogs were given an oral dose of 2.0 mg melatonin prolonged-
release tablets 2 h after dinner. Blood samples (1.0 ml) were
collected into heparinized tubes before (0 h) and at 0.17, 0.33,
0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 10 and 12 h after ad-
ministration.To investigate whether the endogenous melatonin
interfered with the determination or not, 1.0 ml of “blank” blood
sample was collected in accordance with the blood collection
point as administration on the previous day. Plasma was im-
mediately separated by centrifugation and stored at −70 °C until
analysis.
Pharmacokinetic parameters of melatonin were calcu-
lated by non-compartmental method using DAS 3.2 pharmaco-
kinetic program (Chinese Pharmacology Society).The maximum
plasma concentrations (Cmax) and the corresponding peak time
(Tmax) were observed directly from the individual drug plasma
concentration–time profile. The terminal elimination rate
constant (ke) was estimated by log-linear regression of con-
centrations observed during the terminal phase of elimination.
The elimination half-life (t1/2) was calculated as 0.693/ke. The
area under the plasma concentration–time curve was calcu-
lated by the linear trapezoidal rule.
3. Results and discussion
3.1. Method development
3.1.1. Liquid chromatography
Various mobile phase conditions were evaluated in the ex-
periment to obtain optimized responses, suitable retention
times, and good peak shapes. Compared with water, 5 mM am-
monium acetate significantly made the shape of melatonin
more symmetric. Formic acid (0.1%) increased the signal re-
sponse of melatonin. Methanol was found to produce better
elution ability than acetonitrile. Finally, a mobile phase con-
sisting of methanol : 5 mM ammonium acetate : formic acid
(40:60:0.1, v/v/v) was chosen to obtain satisfactory sensitivity
and good retention of melatonin. Under the optimized LC con-
ditions, the retention times of melatonin and the IS were 2.6
and 1.3 min, respectively. The total analytical time was 3.0 min
per sample. It was the shortest analysis time for analyzing mela-
tonin in dog plasma compared to the research published before
which was greatly suitable for high throughput analysis in phar-
macokinetic studies. We also reduce the amount of methanol
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in mobile phase by applying a small particle size C18 column
(2.0 × 50 mm, 3 μm) on chromatographic separation at a flow
rate of 0.2 ml/min.
3.1.2. Mass spectrometry
In our study, the LC-MS/MS analysis was performed in both
positive and negative ion ESI modes.The positive ion mode was
more suitable for quantitative determination because of its
better signal-to-noise ratios. Melatonin was easily ionized in
Turboionspray (TIS) interface to form protonated ion of [M + H]+
at m/z 233.2. The product ion scan spectra of [M + H]+ showed
several major fragment ions at m/z 174.2 and 216.2. Follow-
ing detailed optimization of MS conditions, fragment ion of
melatonin at m/z 174.2 gave higher signal response and lower
noise level than fragment ion at m/z 216.2. Hence ion transi-
tion of m/z 233.2→174.2 was finally chosen for quantification
of melatonin. Similarly, mass transition of m/z 264.2→58.2 was
used for detection of desvenlafaxine (IS), which showed similar
extraction behavior and signal drift trend with melatonin.
Desvenlafaxine is a kind of selective serotonin reuptake in-
hibitor (SSRI) class antidepressant. Uz et al. showed that the
SSRI had a positive effect on arylalkylamine-N-acetyltransferase
gene expression and might modulate melatonin synthesis, but
it only worked in the hippocampus and striatum [45]. In this
experiment, desvenlafaxine was simply added into the plasma
in the process of sample preparation which would not have
interaction with melatonin. So in this study, desvenlafaxine was
chosen as the IS for melatonin. The product ion mass spectra
of melatonin and IS are shown in Fig. 1.
3.2. Sample preparation
Protein precipitation and liquid–liquid extraction (LLE) were
applied and compared for the sample preparation. Marked sup-
pression matrix effect was obtained after protein precipitation.
Liquid–liquid extraction is a more effective method to avoid
matrix effect, thus it was adopted in the present method for
the preparation of samples. Diethyl ether and ethyl acetate were
investigated to identify the more efficient extraction agent for
the sample. To further improve the recovery of the analyte,
sodium carbonate and sodium hydroxide as the alkaline re-
agents at different concentrations were considered. The result
Fig. 1 – Production scan spectra of melatonin (A) and desvenlafaxine (IS, B).
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showed that ethyl acetate and 1 M sodium carbonate offered
better extraction recovery. In this method, only 200 μl of dog
plasma was used in each sample which was enough for the
pharmacokinetic study of melatonin.
3.3. Method validation
3.3.1. Selectivity, carry over and cross-talk
There was no evidence of interfering peaks from endog-
enous compounds at the retention times of melatonin and IS
in all the tested six lots of blank matrix samples. The peak de-
tected in the plasma collected on the previous day before
administration was far less than 20% of the LLOQ. No carry over
peaks were shown after the injection of ULOQ. No cross-talk
peaks were observed between melatonin and IS after the in-
jection of the highest standard on calibration curve and working
solution of IS. Representative chromatograms obtained from
the blank plasma collected at 01:00 AM on the previous day
before administration, blank plasma spiked with melatonin at
the LLOQ and a dog plasma sample taken at 2 h post-dose are
shown in Fig. 2.
3.3.2. Linearity and LLOQ
The linearity was evaluated on three separate days with two
sets of calibration curves per day.The standard curve was con-
structed to span an analytical measuring range of 0.020–10 ng/ml
with good reproducibility and linearity. A typical equation of
the calibration curve on a validation batch was as follows:
y = 0.231x − 0.000206, where y represents the peak area ratio
of melatonin to IS and x represents the plasma concentration
of melatonin.The correlation coefficients of the generated cali-
bration curves were greater than 0.996.The LLOQ was confirmed
to be 0.020 ng/ml, at which the accuracy was within ±16.5% and
the precision was within 15.2% (Table 1).
Yang et al. developed an LC-MS/MS method with an LLOQ
of 0.01 ng/ml [37]. The sensitivity of our method seemed not
as good as theirs. However, our method was in fact more sen-
sitive than the reported method. In the published method,Yang
et al. used a larger plasma volume of 0.5 ml and an injection
volume of 20 μl [37]. In the present study, a 0.2 ml aliquot of
plasma and an injection volume of 10 μl were used, which re-
sulted in absolute sensitivity that was 2.5 times higher than
the reported method. The sensitivity of this method could be
easily improved by increasing the plasma volume and injec-
tion volume. However, this strategy was plasma wasted and
might decrease dogs’ tolerance. In addition, single dose
administration of 2.0 mg melatonin resulted in a Cmax ap-
proximately at 0.40 ng/ml [35]. Therefore, the method with an
LLOQ of 0.020 ng/ml was sensitive enough for pharmacoki-
netic study of melatonin.
3.3.3. Precision and accuracy
The results of intra-day and inter-day precision and accuracy
of the assays are shown in Table 1. The intra- and inter-day
precisions were all below 15% with a maximum RSD of 12.6%,
and accuracy was calculated within 98.2%–105.0%.
3.3.4. Extraction recovery and matrix effect
The recoveries of melatonin extracted from dog plasma were
79.0 ± 6.4, 83.9 ± 4.5 and 79.1 ± 1.2% at the concentrations of 0.04,
0.40 and 8 ng/ml, respectively.The recovery of IS was 90.7 ± 8.1%.
The extraction recoveries of melatonin and IS were consis-
tent and reproducible. The matrix effects of melatonin from
six different lots of dog plasma at concentrations of 0.04, 0.40
and 8.0 ng/ml were in the range of 97.6–104.9% with RSD values
below 6.4%. The matrix effect of IS (1.25 ng/ml in plasma) was
93.9% and the RSD value was 6.9%.
3.3.5. Stability
Table 2 summarizes the results for the stability of melatonin,
which indicated that melatonin was stable in dog plasma after
storage at room temperature for 4.0 h, at −70 °C for 25 d, after
three freeze–thaw cycles at −70 °C, after storage with dry ice
for 2.0 h, and in processed samples at 4 °C for 24 h.
3.4. Pharmacokinetic study and incurred sample stability
The validated LC-MS/MS method was successfully applied to
pharmacokinetic study of melatonin in Beagle dogs after oral
administration of 2.0 mg prolonged-release melatonin. The en-
dogenous melatonin was not detected in all six dogs, thus it did
not have impact on performing pharmacokinetic profiles. The
plasma concentration–time curve (mean ± SD,n = 6) of the analyst
is shown in Fig. 3. The corresponding pharmacokinetic param-
eters are listed in Table 3. The values of half-life and Tmax were
similar to the corresponding data reported by Yang et al. [37],
although the dose employed by those authors was much higher
(6.0 mg each dog).The Cmax and AUC values of melatonin in this
Table 1 – Intra- and inter-day precision and accuracy of
the LC-MS/MS method to determine melatonin in dog
plasma (n = 3 d, 6 replicates per day).
Spiked
concentration
(ng/ml)
Intra-day Inter-day
Precision
(RSD, %)
Accuracy
(RE, %)
Precision
(RSD, %)
Accuracy
(RE, %)
0.020 5.3 16.5 15.2 5.5
0.040 7.1 −1.8 5.8 0.2
0.40 9.4 5.0 12.6 1.5
8.0 1.4 3.2 5.3 1.1
RSD: relative standard deviation; RE: relative error.
Table 2 – Stability of melatonin under different storage
conditions (n = 3).
Storage condition Spiked
concentration
(ng/ml)
Precision
(RSD, %)
Accuracy
(RE, %)
Room temperature
for 4 h
0.040 6.2 3.1
8.0 3.9 5.7
Frozen (−70 °C) for
25 d
0.040 1.3 1.0
8.0 4.5 1.3
Three freeze–thaw
cycles at −70 °C
0.040 5.5 0.9
8.0 1.6 1.4
Transportation for
2 h (dry ice)
0.040 6.7 6.9
8.0 3.1 6.9
Post-pretreatment
at 4 °C for 24 h
0.040 0.6 3.7
8.0 1.8 4.3
RSD: relative standard deviation; RE: relative error.
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Fig. 2 – Representative LC-MS/MS chromatograms for melatonin and desvenlafaxine (IS). (A) Blank plasma collected at 01:00
AM on the previous day before administration; (B) blank plasma spiked with melatonin (0.020 ng/ml) and the IS; and
(C) a dog plasma sample collected 2 h after oral administration of 2.0 mg prolonged-release melatonin tablets.
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study were dose-proportional to the published data, which was
coincident with the linear-pharmacokinetics of melatonin [13].
Harpsoe et al. reported that the t1/2 of melatonin was approxi-
mately 0.75 h in humans following both oral and intravenous
administration routes [46].This result suggested that the elimi-
nation rate of melatonin in dogs was similar to that in humans.
Yeleswaram et al. indicated that the apparent elimination half-
life of melatonin following an intravenous dose of 3 mg/kg was
18.6 min in dogs [47]. The significant shorter elimination rate
might come from the different time points used for the calcu-
lation of t1/2.
In the reanalysis of incurred samples, more than 92.3% of
the assay satisfied the acceptance criteria.
4. Conclusion
A rapid and sensitive LC-MS/MS method has been developed
and validated for the analysis of melatonin in dog plasma.This
method showed high throughput (3.0 min each sample) and
relatively good sensitivity with an LLOQ of 0.020 ng/ml. This
method was successfully applied to the pharmacokinetic study
of prolonged-release melatonin in Beagle dogs.
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